cfDNA |
Cell-free DNA |
CNI |
Copy number instability |
CSC |
Cancer stem cells |
CT scan |
Computed-tomography scanner |
CTLA-4 |
Cytotoxic T-lymphocyte-associated antigen 4 |
ECOG |
Eastern cooperative oncology group |
Fc |
Crystallizable fragment |
FcR |
Crystallizable fragment receptor |
HNSCC |
Head and neck squamous cell carcinoma |
ICI |
Immune checkpoint inhibitor |
iRECIST |
Immune response-evaluation criteria in solid tumors |
irRC |
Immune-related response criteria |
irRECIST |
Immune-related response-evaluation criteria in solid tumors |
NGS |
Next-generation sequencing |
NSCLC |
Non-small-cell lung cancer |
OS |
Overall survival |
PD-1 |
Programmed cell death protein 1 |
PD-L1 |
Programmed cell death ligand 1 |
PD-L2 |
Programmed cell death ligand 2 |
RECIST |
Response-evaluation criteria in solid tumors |
TAM |
Tumor-associated macrophage |
TGK |
Tumor growth kinetics |
TGR |
Tumor growth rate |
TILs |
Tumor-infiltrating T lymphocytes |
Tregs |
Regulatory T-cells |
TTF |
Time to treatment failure |
uPD |
Unconfirmed progressive disease |